NA
Niagen Bioscience Inc
NAGE · NASDAQ
$2.99 +0.17% (+$0.01)
1M -6.85%
Market Cap $238.1M
P/E Ratio 14.89x
Div. Yield -
ROE 20.50%
Bulios Fair Price
$3.59
20.1% upside
Current Price
$2.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NAGE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
67 /100
Cheap PEG 0.13x
P/E 14.89x
P/B 2.89x
Growth
100 /100
Growing Book val. growth 38.72%
Rev. growth 21.56%
FCF growth N/A
Profitability
54 /100
Moderate Op. margin 6.67%
Gross margin 64.24%
FCF margin 4.40%
Quality
77 /100
Excellent ROA 15.00%
ROIC 8.75%
Asset turnover 1.21x
Debt
100 /100
Low Net debt/EBITDA -3.49x
Debt/Equity 0.03x
Current ratio 6.50x
Stability
36 /100
Moderate EPS volatility 109.64%
Beta 2.09x
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NAGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert N. Fried
Employees
117
Headquarters
Los Angeles
Upcoming events
03 NOV
Earnings
Upcoming earnings report